Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience Case report
Article Sidebar
Main Article Content
Abstract
Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabazantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. The Lancet Oncology 2016; 7(17): 917-927.
3. Rak nerki. Współczesna diagnostyka i terapia. II ed. Szczylik C, Escudier B, Porta C (ed.). Termedia, 2017.
4. Lewiński A, Płaczkiewicz-Jankowska E. Niedoczynność tarczycy. In: Gajewski P (ed.): Interna Szczeklika 2015/16. Medycyna Praktyczna, Kraków 2015: 694-700.
5. Kust D, Prpić M, Krujac I et al. Thyrosine kinase inhibitors and hypothyroidism – an intriguing link. Endocrine Oncology and Metabolism 2016; 2(2): 102-113. https://doi.org/1021040/eom/2016223.
6. Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011; 117: 534-544.
7. Yavuz S, Apolo AB, Kummar S et al. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma Thyroid 2014; 24(8): 1223-1231.
8. Jazvić M, Prpić M, Jukić T et al. Sunitinib-induced thyreotoxicosis – a not so rare entity. Anticancer Res 2015; 35: 481-485.
9. Riesenbeck IM, Bierer S, Hoffmeister I et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2011; 29: 207-213.
10. Baldazzi V, Tassi R, Lapini A et al. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2012; 30: 704-710.
11. Kust D, Prpić M, Murgić J et al. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy Anticancer Res 2014; 34: 3177-3184.
12. Wang JF, Milosveski V, Schramek C et al. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998; 157: 5-12.
13. Kappers MH, van Esch JH, Smeets FM et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodination J Clin Endocrinol Metab 2010; 95: 3758-3762.
14. Mannavola D, Coco P, Vannucchi G et al. A novel thyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake J Clin Endocrinol Metab 2007; 92: 3531-3534.
15. Pani F, Atzori F, Baghino G et al. Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved? Thyroid 2015; 25: 1255-1261.
16. Kitajima K, Takahashi S, Maeda T et al. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. Eur J Radiol 2012; 81(9): 2060-2065.
17. Clemons J, Gao D, Naam M et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib Clin Genitourin. Cancer 2012; 10: 225-231.
18. Daimon M, Kato T, Kaino W et al: Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42(8): 742-747.
19. Davie FB, Tang HY, Shih A et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006; 66: 7270-7275.
20. Goodman AD, Hoekstra SJ, Marsh PS et al. Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7,12-dimethylbenz(a)anthracene in the rat. Cancer Res 1980; 40: 2336-2342.
21. Nelson M, Hercbergs A, Rybicki L et al. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132: 1041-1046.
22. Trentin AG, Alvarez-Silva M, Moura Neto V et al. Thyroid hormone induces cerebellar astrocytes and C6 glioma cells to secrete mitogenic growth factors. Am J Physiol Endocrinol Metab 2001; 281: E1088-E1094.